RSPI (RespireRx Pharmaceuticals) Research & Development: $0.31 Mil (TTM As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Research & Development?

RespireRx Pharmaceuticals RSPI 12 Research & Development is $0.31 Mil as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. RespireRx Pharmaceuticals's Research & Development for the three months ended in Sep. 2023 was $0.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was $0.31 Mil.

RespireRx Pharmaceuticals  (OTCPK:RSPI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

RespireRx Pharmaceuticals Research & Development Related Terms

RespireRx Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Research & Development Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.60 0.64 0.70 0.43

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.03 0.10 0.10 0.09
RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.31 Mil mean?
RespireRx Pharmaceuticals (RSPI) has a Research & Development of $0.31 Mil as of Sep. 2023. Research and development expense is the total cost for research and development activities. View historical data on RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Research & Development too high?
RespireRx Pharmaceuticals' current Research & Development is $0.31 Mil. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Research & Development compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Research & Development of $0.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Research & Development is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Research & Development of $0.31 Mil. The current Research & Development is $0.31 Mil. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Research & Development is $0.31 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price